Peripheral artery disease: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• BTK 9
• GLP-1 1
• SGLT2 1
• PCSK9 1
• APOE 0
• HIF-1 0
• PPAR 0
• VEGF 0
• AKT 0
• ERK 0
• ABL1 0
• CCR5 0
• IL-17 1
• IL-6 0
• KEAP1 0
• NLRP3 0
• NRF2 1
• PTEN 0
• RUNX1 0
• STAT3 0
• TNF 0
• TP53 0
• TREM2 0

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NHLBI · R44

  Development and Chronic Preclinical Assessment of a Flexible Endovascular Scaffold for Treating Stenosis in the Femoropopliteal Arterial Segments

  Ev2 Technologies, Inc.· Pittsburgh, United States· US$918,166 awarded in fiscal year 2026· until Aug 2028

• NIH NHLBI · R01

  Immune-mediated mechanisms of VEGF-A165 alternative splicing in angiogenesis in the context of Advanced Aging

  Ocean State Research Institute, Inc.· Providence, United States· US$514,340 awarded in fiscal year 2026· until May 2031

• NIH NHLBI · R43

  Development of combined U-turn catheter and self-anchoring sheath system for turning direction of established percutaneous vascular access

  Upstream Access, Inc· Camden, United States· US$320,893 awarded in fiscal year 2026· until Mar 2027

• NIH NIA · R21

  Urolithin A to Improve Mitochondria and Mobility in Peripheral Artery Disease: Urolithin for PAD Trial

  Northwestern University· Chicago, United States· US$214,006 awarded in fiscal year 2026· until Aug 2028

• NIH NIBIB · F32

  Bedside oximetry system for minimally invasive quantitative measurement and monitoring of tissue oxygenation.

  Dartmouth College· Hanover, United States· US$76,780 awarded in fiscal year 2026· until Sept 2027

• European Commission (Horizon Europe) · HORIZON-ERC

  From niche to function: how endothelial cell interactions orchestrate muscle function in health and disease (InterECt)

  Eidgenoessische Technische Hochschule Zuerich· Zuerich, Switzerland· EU contribution €2,498,888· until Apr 2032

• European Commission (Horizon Europe) · HORIZON-ERC

  Single cEll guided polygeniC Risk prEdicTion of ASCVD (SECRET)

  Ita-Suomen Yliopisto· Kuopio, Finland· EU contribution €2,000,000· until Jun 2029

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-EIC

  MultiomIcs based Risk stratification of Atherosclerotic CardiovascuLar disEase (MIRACLE)

  Ita-Suomen Yliopisto· Kuopio, Finland· EU contribution €4,599,866· until Sept 2027· 6 countries

• European Commission (Horizon Europe) · HORIZON-RIA

  PERSONALIZED REHABILITATION VIA NOVEL AI PATIENT STRATIFICATION STRATEGIES (PREPARE)

  Aristotelio Panepistimio Thessalonikis· Thessaloniki, Greece· EU contribution €5,774,113· until May 2027· 9 countries

• European Commission (Horizon Europe) · HORIZON-RIA

  DEVELOPING TRUSTWORTHY ARTIFICIAL INTELLIGENCE (AI)-DRIVEN TOOLS TO PREDICT VASCULAR DISEASE RISK AND PROGRESSION (VASCUL-AID)

  Stichting Amsterdam Umc· Amsterdam, Netherlands· EU contribution €5,969,125· until Apr 2029· 10 countries

10 of 216 running projects, newest first. Listed amounts together: US$125.3m + €20.8m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Trials whose registry record says individual participant data (IPD) will be shared.

No trial in this view states that it shares participant data.

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 1
• Mendelian Randomization Analysis 18
• CRISPR-Cas Systems 1
• Gene Expression Profiling 5
• Proteomics 9
• Metabolomics 6
• Flow Cytometry 1
• Positron-Emission Tomography 3
• Magnetic Resonance Imaging 9
• Machine Learning 18
• Deep Learning 5
• Cohort Studies 53
• Genome-Wide Association Study 22

• Residual lipid-related proteomic and metabolomic signatures associated with major adverse cardiovascular events after revascularization in peripheral artery disease.

  BMC Cardiovasc Disord, Sept 2026

• Mitochondrial Omics in Macrophage Foam Cell Formation and Atherosclerosis.

  Proteomics, Aug 2026

• Proteomic insights of peripheral artery disease across the glycemic spectrum: a prospective cohort study.

  Metabolism, Aug 2026

• Shared proteomic landscape between arteriosclerosis and cardiovascular endpoints: a Mendelian randomization and observational study integrating AlphaFold3 for structural prediction.

  Cardiovasc Res, Jun 2026

• Identification of multi-omic pleiotropy factors for peripheral artery disease.

  Hum Mol Genet, May 2026

• Blood pressure, proteomic vascular ageing, and incident cardiovascular disease.

  Eur J Prev Cardiol, May 2026

• Enhanced Prediction of Peripheral Artery Disease Using Plasma Proteomics Among Individuals Without Diabetes.

  J Am Heart Assoc, May 2026

• Proteomics-derived organ-specific aging clusters predict macrovascular and microvascular complications in diabetes.

  Cardiovasc Diabetol, Feb 2026

• Proteomic signature of metabolic dysfunction-associated steatotic liver disease and risk of atherosclerotic cardiovascular disease.

  Cardiovasc Diabetol, Dec 2025

See which targets of this disease your abstract mentions, and go to the people working on them.